Meeting
2020 Gastrointestinal Cancers Symposium
A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.
Authors
Benjamin Leon Musher
Baylor College of Medicine, Houston, TX
Benjamin Leon Musher , Brandon George Smaglo , Wasif Abidi , Mohamed Othman , Kalpesh Patel , James Jing , Nir Stanietzky , Jinyu (Jim) Lu , Amanda Brisco , Jessica Wenthe , Emma Eriksson , Ann M. Leen , Susan G. Hilsenbeck , Gustav J. Ullenhag , Eric Keith Rowinsky , Bambj Grilley , Angelica Sara Ingrid Loskog , Benjamin Brenner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02705196
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 716)
Abstract #
716
Poster Bd #
L5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.
First Author: Benjamin Leon Musher
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nab-paclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Anita Ahmed Turk
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).
First Author: John Davelaar